| Name | Title | Contact Details |
|---|---|---|
Jinhee Chang |
Intellectual Property Counsel | Profile |
Fred Medick |
General Counsel | Profile |
Aviva Gilbert |
Assistant General Counsel, Senior | Profile |
Yan Qi |
Director and Assistant General Counsel, Platforms | Profile |
Sarah Tully |
Director and Assistant General Counsel | Profile |
Leading innovator in Life Science Laboratory Consumables: Pipette Tips; PCR; Screw Cap, Centrifuge, and Cryogenic Tubes; HTS; and Tubes Racks.
Alberta Conservation Association is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Banyan Biomarkers Inc is a Alachua, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.